FULC – fulcrum therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Fulcrum Therapeutics (NASDAQ:FULC) shareholders have endured a 77% loss from investing in the stock three years ago [Yahoo! Finance]
Accent Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of ATX-559 and Chief Scientific Officer Transition [Yahoo! Finance]
Fulcrum Therapeutics to Participate in Upcoming December Conferences
Fulcrum Therapeutics Third Quarter 2024 Earnings: US$0.35 loss per share (vs US$0.39 loss in 3Q 2023) [Yahoo! Finance]
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) had its "sector perform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $4.00 price target on the stock.
Form 8-K Fulcrum Therapeutics, For: Dec 18
Form SC 13G Fulcrum Therapeutics, Filed by: BlackRock, Inc.
Form SCHEDULE 13G Fulcrum Therapeutics, Filed by: Nantahala Capital Management, LLC
Form SC 13G/A Fulcrum Therapeutics, Filed by: SUVRETTA CAPITAL MANAGEMENT, LLC
Form 4 Fulcrum Therapeutics, For: Nov 12 Filed by: King Rachel K.
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.